<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MORPHINE SULFATE- morphine sulfate tablet </strong><br>Dispensing Solutions, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Morphine Sulfate Tablets safely and effectively. See full prescribing information for Morphine Sulfate Tablets.<br><br>Morphine Sulfate Tablets, CII<br>Initial U.S. Approval: 1984</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Morphine sulfate is an opioid analgesic indicated for the relief of moderate to severe acute and <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> where an opioid analgesic is appropriate. (<a href="#i4i_indications_id_7b8ee8dc-9cab-4174-a854-1ce78815ff4a">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul><li>Morphine Sulfate Tablets: 15 to 30 mg every 4 hours as needed. (<a href="#i4i_section_id_aa5bd38e-db94-45c8-9dfd-598dce3c53a4">2.2</a>)</li></ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 15 mg or 30 mg. (<a href="#i4i_dosage_form_strength_id_50f24950-c66a-49a5-87a0-fcb3c2024f14">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to morphine. (<a href="#i4i_contraindications_id_808e3140-b9e2-417d-94a7-ddb1f0456470">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> in the absence of resuscitative equipment. (<a href="#i4i_contraindications_id_808e3140-b9e2-417d-94a7-ddb1f0456470">4</a>)</li>
<li>Acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>. (<a href="#i4i_contraindications_id_808e3140-b9e2-417d-94a7-ddb1f0456470">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span>. (<a href="#i4i_contraindications_id_808e3140-b9e2-417d-94a7-ddb1f0456470">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>: Increased risk in elderly, debilitated patients, those suffering from conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or upper airway obstruction. (<a href="#i4i_section_id_43d879d8-beb3-421a-b649-c746e0d6973d">5.1</a>)</li>
<li>Controlled substance: Morphine sulfate is a Schedule II controlled substance with an abuse liability similar to other opioids. (<a href="#i4i_section_id_5234fb4a-aac6-42b4-90ef-27a97b7beeef">5.2</a>)</li>
<li>CNS effects: Additive CNS depressive effects when used in conjunction with alcohol, other opioids, or illicit drugs. (<a href="#i4i_section_id_ab9507cb-ee75-41d8-bb5f-3520318e734e">5.3</a>)</li>
<li>Elevation of intracranial pressure: May be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions. (<a href="#i4i_section_id_bca15727-25d4-4f19-81e0-dd36c1f264eb">5.4</a>)</li>
<li>Hypotensive effect: Increased risk with compromised ability to maintain blood pressure. (<a href="#i4i_section_id_7114d526-d47a-422d-a118-1810a4e79cd4">5.5</a>)</li>
<li>Prolonged gastric obstruction: In patients with <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span>, especially <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. (<a href="#i4i_section_id_25f25fa5-edc8-4adb-a687-bb5313b3afd9">5.6</a>)</li>
<li>Sphincter of Oddi spasm and diminished biliary/pancreatic secretions. Increased risk with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>. (<a href="#i4i_section_id_1852dd94-64bc-4a33-b079-d00f2c61c7e8">5.7</a>)</li>
<li>Special Risk Groups: Use with caution and in reduced dosages in patients with severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, Addison's disease, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, elderly, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> and <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>, may aggravate or induce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. (5.8)</li>
<li>Impaired mental/physical abilities: Caution must be used with potentially hazardous activities. (<a href="#i4i_section_id_d033c5a4-085e-4865-ab36-bc2ced190d52">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions seen on initiation of therapy are: <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, and <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>. (<a href="#i4i_adverse_effects_id_b6c45d2e-130e-4c3c-b06f-1e348f57d92d">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Roxane Laboratories, Inc. at (614) 276-4000 or Technical Product Information (800) 962-8364 or FDA at<br>1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>CNS depressants: Increased risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Use with caution in reduced dosages. (<a href="#i4i_section_id_440d012d-2ca4-4ec7-a024-3868dab4e45e">7.1</a>)</li>
<li>Muscle relaxants: Enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. (<a href="#i4i_section_id_774c08c6-5522-4a2e-8613-0c5679fcc9d0">7.2</a>)</li>
<li>Mixed agonist/antagonist opioid analgesics (i.e. pentazocine, nalbuphine, and butorphanol): May reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> and/or may precipitate withdrawal symptoms. (<a href="#i4i_section_id_42d87620-03a2-43cb-bca5-45d34e0a1cb3">7.3</a>)</li>
<li>Cimetidine: Precipitates <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>. (<a href="#i4i_section_id_5fd9265f-33d9-4e78-a9f6-b761bd6eee79">7.4</a>)</li>
<li>Monoamine oxidase inhibitors (MAOIs): Potentiate the action of morphine sulfate. Morphine sulfate should not be used in patients taking MAOIs or within 14 days of stopping such treatment. (<a href="#i4i_section_id_d89c73c6-8c6d-4632-bcc2-da1d21e787d0">7.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Geriatric patients (<a href="#i4i_geriatric_use_id_5b32ea8b-81b3-40f6-a2eb-ec9bf9c3a968">8.5</a>), <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> (<a href="#i4i_section_id_2a59fb86-c230-48bd-9b87-fd36846c6a5e">8.7</a>), <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (<a href="#i4i_section_id_2a3b0cec-509f-4e69-8c1e-ef311d583cd8">8.8</a>): Use caution during dose selection, starting at the low end of the dosing range while carefully monitoring for side effects.</li></ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Individualization of Dosage </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Initiation of Therapy in Opioid-Naïve Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Conversion to Oral Morphine Sulfate </a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Maintenance of Therapy</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Cessation of Therapy </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Misuse, Abuse and Diversion of Opioids </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Interactions with Alcohol and Drugs of Abuse</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use In <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hypotensive Effect</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Gastrointestinal Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Special Risk Groups</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Driving and Operating Machinery</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CNS Depressants</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Muscle Relaxants </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Mixed Agonist/Antagonist Opioid Analgesics </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Cimetidine </a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Anticholinergics</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 P-Glycoprotein (PGP) Inhibitors</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Gender</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Symptoms</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Treatment</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Information for Patients and Caregivers</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_7b8ee8dc-9cab-4174-a854-1ce78815ff4a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> where use of an opioid analgesic is appropriate.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_94261fb9-045e-405c-b366-220c961aa97f"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Selection of patients for treatment with morphine sulfate should be governed by the same principles that apply to the use of similar opioid analgesics. Individualize treatment in every case, using non-opioid analgesics, opioids on an as needed basis and/or combination products, and chronic opioid therapy in a progressive plan of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality, and the American <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Society.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27ce9863-ff21-4f53-9763-118ef843858f"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Individualization of Dosage </h2>
<p class="First">As with any opioid drug product adjust the dosing regimen for each patient individually, taking into account the patient’s prior analgesic treatment experience. In the selection of the initial dose of morphine sulfate, give attention to the following:</p>
<ul>
<li>the total daily dose, potency and specific characteristics of the opioid the patient has been taking previously;</li>
<li>the reliability of the relative potency estimate used to calculate the equivalent morphine sulfate dose needed;</li>
<li>the patient’s degree of opioid tolerance;</li>
<li>the general condition and medical status of the patient;</li>
<li>concurrent medications;</li>
<li>the type and severity of the patient’s <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>;</li>
<li>risk factors for abuse, addiction or diversion, including a prior history of abuse, addiction or diversion.</li>
</ul>
<p>The following dosing recommendations, therefore, can only be considered suggested approaches to what is actually a series of clinical decisions over time in the management of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of each individual patient. </p>
<p>Continual re-evaluation of the patient receiving morphine sulfate is important, with special attention to the maintenance of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control and the relative incidence of side effects associated with therapy. During chronic therapy, especially for non-cancer-related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, periodically re-assess the continued need for the use of opioid analgesics.</p>
<p>During periods of changing analgesic requirements, including initial titration, frequent contact is recommended between physician, other members of the healthcare team, the patient, and the caregiver/family. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa5bd38e-db94-45c8-9dfd-598dce3c53a4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Initiation of Therapy in Opioid-Naïve Patients</h2>
<p class="First">Start patients who have not been receiving opioid analgesics on morphine sulfate in the following dosing range using tablets, 15 mg or 30 mg strengths:</p>
<dl>
<dt></dt>
<dd>Morphine Sulfate Tablets: 15 to 30 mg every 4 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </dd>
</dl>
<p>Titrate the dose based upon the individual patient’s response to their initial dose of morphine sulfate. Adjust the dose to an acceptable level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> taking into account the improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity and the tolerability of the morphine by the patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97d051e9-139d-4e96-a105-694cd7960ba3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Conversion to Oral Morphine Sulfate </h2>
<p class="First">There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dose of morphine sulfate. It is better to underestimate a patient’s 24-hour oral morphine sulfate dose and make available rescue medication than to overestimate the 24-hour oral morphine sulfate dose and manage an adverse experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
<p>Consider the following general points regarding opioid conversions. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99abed7f-81aa-4a26-b183-b4545f85fbda"></a><a name="section-2.3.1"></a><p></p>
<h3>Conversion From Parenteral Morphine to Oral Morphine Sulfate</h3>
<p class="First">For conversion from parenteral to oral morphine sulfate, anywhere from 3 to 6 mg of oral morphine sulfate may be required to provide <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief equivalent to 1 mg of parenteral morphine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_edb52c5c-7b3a-443a-b585-523fd2deb154"></a><a name="section-2.3.2"></a><p></p>
<h3>Conversion From Parenteral Oral Non-Morphine Opioids to Oral Morphine Sulfate  </h3>
<p class="First">In converting patients from other opioids to morphine sulfate, close observation and adjustment of dosage based upon the patient’s response to morphine sulfate is imperative. Physicians and other healthcare professionals are advised to refer to published relative potency information, keeping in mind that conversion ratios are only approximate. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_189a3be6-60d8-4743-a5cf-5dce8bb76de7"></a><a name="section-2.3.3"></a><p></p>
<h3>Conversion From Controlled-Release Oral Morphine to Oral Morphine Sulfate </h3>
<p class="First">For a given dose, the same total amount of morphine sulfate is available from Morphine Sulfate Tablets, Morphine Sulfate Oral Solution, and controlled-release and extended-release morphine capsules. The extended duration of release of morphine sulfate from controlled-release tablets or extended-release tablets results in reduced maximum and increased minimum plasma morphine sulfate concentrations than with shorter acting morphine sulfate products. Conversion from oral solution or immediate-release tablets to the same total daily dose of controlled-release tablets or extended-release tablets could lead to excessive sedation at peak serum levels. Therefore, dosage adjustment with close observation is necessary. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_517a319a-a9b3-406e-b5b4-c264cf78a527"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Maintenance of Therapy</h2>
<p class="First">Continual re-evaluation of the patient receiving morphine sulfate is important, with special attention to the maintenance of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> control and the relative incidence of side effects associated with therapy. If the level of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> increases, effort should be made to identify the source of increased <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, while adjusting the dose as described above to decrease the level of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. During chronic therapy, especially for non-cancer-related <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> associated with other terminal illnesses), periodically reassess the continued need for the use of opioid analgesics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20f3f123-a419-4204-9344-4502de144437"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Cessation of Therapy </h2>
<p class="First">When the patient no longer requires therapy with morphine sulfate, gradually taper the dose to prevent signs and symptoms of withdrawal in the physically dependent patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_50f24950-c66a-49a5-87a0-fcb3c2024f14"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Each 15 mg tablet for oral administration contains: morphine sulfate 15 mg and is a white, biconvex tablet scored on one side and product identification "54 733" debossed on the other side.</p>
<p>Each 30 mg tablet for oral administration contains: morphine sulfate 30 mg and is a white, biconvex tablet scored on one side and product identification "54 262" debossed on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_808e3140-b9e2-417d-94a7-ddb1f0456470"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Morphine sulfate is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to morphine, morphine salts, or any components of the product.</p>
<p>Morphine sulfate is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the absence of resuscitative equipment. </p>
<p>Morphine sulfate is contraindicated in patients with acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>.</p>
<p>Morphine sulfate is contraindicated in any patient who has or is suspected of having <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_7d5c2a8b-c9fa-45ea-92f4-d4d84e102631"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43d879d8-beb3-421a-b649-c746e0d6973d"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is the primary risk of morphine sulfate. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.</p>
<p>Use morphine sulfate with extreme caution in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> or <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span> and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, or pre-existing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In such patients, even usual therapeutic doses of morphine sulfate may increase airway resistance and decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Consider alternative non-opioid analgesics, and use morphine sulfate only under careful medical supervision at the lowest effective dose in such patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5234fb4a-aac6-42b4-90ef-27a97b7beeef"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Misuse, Abuse and Diversion of Opioids </h2>
<p class="First">Morphine sulfate is an opioid agonist and a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty.</p>
<p>Morphine sulfate can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing morphine sulfate in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.</p>
<p>Morphine sulfate may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Italics">[See <a href="#i4i_abuse_dependence_id_9507ade2-54c9-4bce-943b-114c6e4e4340">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> (9)</a>]</span></p>
<p>Concerns about abuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab9507cb-ee75-41d8-bb5f-3520318e734e"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Interactions with Alcohol and Drugs of Abuse</h2>
<p class="First">Morphine sulfate may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> because <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bca15727-25d4-4f19-81e0-dd36c1f264eb"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use In <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">In the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions or a preexisting increase in intracranial pressure, the possible respiratory depressant effects of morphine sulfate and its potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO<span class="Sub">2</span> retention) may be markedly exaggerated. Furthermore, morphine sulfate can produce effects on pupillary response and consciousness, which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7114d526-d47a-422d-a118-1810a4e79cd4"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hypotensive Effect</h2>
<p class="First">Morphine sulfate may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in an individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume or concurrent administration of drugs such as phenothiazines or general anesthetics. Morphine sulfate may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in ambulatory patients.</p>
<p>Administer morphine sulfate with caution to patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, as vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25f25fa5-edc8-4adb-a687-bb5313b3afd9"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Gastrointestinal Effects</h2>
<p class="First">Do not administer morphine sulfate to patients with <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span>, especially <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> because morphine sulfate diminishes propulsive peristaltic waves in the gastrointestinal tract and may prolong the obstruction.</p>
<p>The administration of morphine sulfate may obscure the diagnosis or clinical course in patients with acute abdominal condition.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1852dd94-64bc-4a33-b079-d00f2c61c7e8"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></h2>
<p class="First">Use morphine sulfate with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, as morphine sulfate may cause spasm of the sphincter of Oddi and diminish biliary and pancreatic secretions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d6f3ad4-d0c5-4501-90a6-8bb53dc35d14"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Special Risk Groups</h2>
<p class="First">Use morphine sulfate with caution and in reduced dosages in patients with severe renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, Addison’s disease, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, and in elderly or debilitated patients. <span class="Italics">[See <a href="#i4i_specific_populations_id_3bceb606-db8f-4774-a89a-e58b8a200922">USE IN SPECIFIC POPULATIONS (8.5)</a>]</span></p>
<p>Exercise caution in the administration of morphine sulfate to patients with <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> and <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>.</p>
<p>All opioids may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and all opioids may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings.</p>
<p>Keep Morphine Sulfate Tablets out of the reach of children. In case of accidental ingestion, seek emergency medical help immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d033c5a4-085e-4865-ab36-bc2ced190d52"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Driving and Operating Machinery</h2>
<p class="First">Caution patients that morphine sulfate could impair the mental and/or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery.</p>
<p>Caution patients about the potential combined effects of morphine sulfate with other CNS depressants, including other opioids, phenothiazines, sedative/hypnotics and alcohol. <span class="Italics">[See <a href="#i4i_interactions_id_537c10bb-070d-4fa8-a8f4-4782c9542f63">DRUG INTERACTIONS (7)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b6c45d2e-130e-4c3c-b06f-1e348f57d92d"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions associated with morphine sulfate use include: <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, and to a lesser degree, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p>The common adverse reactions seen on initiation of therapy with morphine sulfate are dose-dependent and are typical opioid-related side effects. The most frequent of these include <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Other commonly observed adverse reactions include: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. The frequency of these events depends upon several factors including clinical setting, the patient’s level of opioid tolerance, and host factors specific to the individual. Anticipate and manage these events as part of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> therapy.</p>
<p>Other less frequently observed adverse reactions expected from opioid analgesics, including morphine sulfate include: </p>
<p><span class="Italics">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, withdrawal syndrome</p>
<p><span class="Italics">Cardiovascular System</span>: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Italics">Digestive System</span>: <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p><span class="Italics">Hemic and Lymphatic System</span>: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Italics">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></p>
<p><span class="Italics">Musculoskeletal:</span> skeletal <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span></p>
<p><span class="Italics">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, vasodilation, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Italics">Respiratory System</span>: <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span></p>
<p><span class="Italics">Skin and Appendages</span>: <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Italics">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span></p>
<p><span class="Italics">Urogenital System: </span><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, anti-<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_537c10bb-070d-4fa8-a8f4-4782c9542f63"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_440d012d-2ca4-4ec7-a024-3868dab4e45e"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CNS Depressants</h2>
<p class="First">Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, profound sedation, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Use morphine sulfate with caution and in reduced dosages in patients taking these agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_774c08c6-5522-4a2e-8613-0c5679fcc9d0"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Muscle Relaxants </h2>
<p class="First">Morphine sulfate may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42d87620-03a2-43cb-bca5-45d34e0a1cb3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Mixed Agonist/Antagonist Opioid Analgesics </h2>
<p class="First">Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as morphine sulfate. In these patients, mixed agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> and/or may precipitate withdrawal symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5fd9265f-33d9-4e78-a9f6-b761bd6eee79"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Cimetidine </h2>
<p class="First">Concomitant administration of morphine sulfate and cimetidine has been reported to precipitate <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> in an isolated report. Monitor patients for increased respiratory and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> when receiving cimetidine concomitantly with morphine sulfate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d89c73c6-8c6d-4632-bcc2-da1d21e787d0"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class="First">MAOIs markedly potentiate the action of morphine sulfate. Allow at least 14 days after stopping treatment with MAOIs before initiating treatment with morphine sulfate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57ad1637-1ea2-4255-9299-f4753325aed6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Anticholinergics</h2>
<p class="First">Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> and/or severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, which may lead to <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55052e78-c68f-41f9-9dbb-ad4c3479735a"></a><a name="section-7.7"></a><p></p>
<h2>7.7 P-Glycoprotein (PGP) Inhibitors</h2>
<p class="First">Based on published reports, PGP inhibitors (e.g. quinidine) may increase the absorption/exposure of morphine sulfate by about two fold. Therefore, exercise caution when morphine sulfate is co-administered with PGP inhibitors.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_3bceb606-db8f-4774-a89a-e58b8a200922"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_223fd273-51c5-4599-ace7-85d2de002460"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4743f32c-88f8-4c39-9b8c-588ac67ec2cb"></a><a name="section-8.1.1"></a><p></p>
<h3>Teratogenic Effects (Pregnancy Category C)</h3>
<p class="First">Animal reproduction studies have not been conducted with morphine sulfate. It is also not known whether morphine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Only give morphine sulfate to a pregnant woman if clearly needed.</p>
<p>In humans, the frequency of congenital anomalies has been reported to be no greater than expected among the children of 70 women who were treated with morphine sulfate during the first four months of pregnancy or in 448 women treated with this drug anytime during pregnancy. Furthermore, no malformations were observed in the infant of a woman who <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span> by taking an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of morphine sulfate and other medication during the first trimester of pregnancy.</p>
<p>Several literature reports indicate that morphine sulfate administered subcutaneously during the early gestational period in mice and hamsters produced neurological, soft tissue and skeletal abnormalities. With one exception, the effects that have been reported were following doses that were maternally toxic and the abnormalities noted were characteristic to those observed when maternal toxicity is present. In one study, following subcutaneous infusion of doses greater than or equal to 0.15 mg/kg to mice, <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span>, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">intestinal hemorrhage</span>, split supraoccipital, malformed sternebrae, and malformed xiphoid were noted in the absence of maternal toxicity. In the hamster, morphine sulfate given subcutaneously on gestation day 8 produced <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span> and cranioschisis. Morphine sulfate was not a significant teratogen in the rat at exposure levels significantly beyond that normally encountered in clinical practice. In one study however, decreased litter size and viability were observed in the offspring of male rats administered morphine at doses approximately 3-fold the maximum recommended human daily dose (MRHDD) for 10 days prior to mating. In two studies performed in the rabbit, no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was reported at subcutaneous doses up to 100 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_835518d9-70b7-4df8-a347-8a8ee17c6d38"></a><a name="section-8.1.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Controlled studies of chronic <span class="Italics">in utero</span> morphine exposure in pregnant women have not been conducted. Infants born to mothers who have taken opioids chronically may exhibit withdrawal symptoms following birth, reversible reduction in brain volume, small size, decreased ventilatory response to CO<span class="Sub">2</span> and increased risk of <span class="product-label-link" type="condition" conceptid="435937" conceptname="Sudden infant death syndrome">sudden infant death syndrome</span>. </p>
<p>Manifestations of the neonatal withdrawal syndrome include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, abnormal sleep pattern, high-pitched cry, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and failure to gain weight. The time and amount of the mother’s last dose and the rate of elimination of the drug from the newborn may affect the onset, duration, and severity of the disorder. When severe symptoms occur, pharmacologic intervention may be required.</p>
<p>Published literature has reported that exposure to morphine sulfate during pregnancy is associated with reduction in growth and a host of behavioral abnormalities in the offspring of animals. Morphine sulfate treatment during gestational periods of organogenesis in rats, hamsters, guinea pigs and rabbits resulted in the following treatment-related embryotoxicity and neonatal toxicity in one or more studies: decreased litter size, embryo-fetal viability, fetal and neonatal body weights, absolute brain and cerebellar weights, lengths or widths at birth and during the neonatal period, delayed motor and sexual maturation, and increased neonatal mortality, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> and <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>. Decreased fertility in female offspring, and decreased plasma and testicular levels of luteinizing hormone and testosterone, decreased testes weights, seminiferous tubule shrinkage, germinal cell <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, and decreased spermatogenesis in male offspring were also observed. Behavioral abnormalities resulting from chronic morphine sulfate exposure of fetal animals included altered reflex and motor skill development, mild withdrawal, and altered responsiveness to morphine sulfate persisting into adulthood.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_07afd168-0619-4b30-bffb-a5e804f560a5"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Opioids cross the placenta and may produce <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and psycho-physiologic effects in neonates. Morphine sulfate is not recommended for use in women during and immediately prior to labor. Occasionally, opioid analgesics may prolong labor through actions which temporarily reduce the strength, duration and frequency of uterine contractions. However this effect is not consistent and may be offset by an increased rate of cervical dilatation, which tends to shorten labor. Closely observe neonates whose mothers received opioid analgesics during labor for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Have a specific opioid antagonist, such as naloxone or nalmefene, available for reversal of opioid-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the neonate. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_cbd3996c-005d-470e-b61f-9b46948e0e5d"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Low levels of morphine sulfate have been detected in maternal milk. The milk:plasma morphine AUC ratio is about 2.5:1. The amount of morphine sulfate delivered to the infant depends on the plasma concentration of the mother, the amount of milk ingested by the infant, and the extent of first-pass metabolism. Because of the potential for serious adverse reactions in nursing infants from morphine sulfate including <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, sedation and possibly withdrawal symptoms, upon cessation of morphine sulfate administration to the mother, decide whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_654c45c0-b69f-45dc-8144-e1062e4e0163"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness and the pharmacokinetics of Morphine Sulfate Tablets in pediatric patients below the age of 18 have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_5b32ea8b-81b3-40f6-a2eb-ec9bf9c3a968"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Elderly patients (aged 65 years or older) may have increased sensitivity to morphine sulfate.   In general, use caution when selecting a dose for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20dad095-720a-4786-bca3-e99dfac1c9e4"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Gender</h2>
<p class="First">While evidence of greater post-operative morphine sulfate consumption in men compared to women is present in the literature, clinically significant differences in analgesic outcomes and pharmacokinetic parameters have not been consistently demonstrated. Some studies have shown an increased sensitivity to the adverse effects of morphine sulfate, including <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, in women compared to men. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a59fb86-c230-48bd-9b87-fd36846c6a5e"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Morphine sulfate pharmacokinetics have been reported to be significantly altered in patients with cirrhosis. Clearance was found to decrease with a corresponding increase in half-life. The M3G and M6G to morphine AUC ratios also decreased in these subjects, indicating diminished metabolic activity. Start these patients cautiously with lower doses of morphine sulfate and titrate slowly while carefully monitoring for side effects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a3b0cec-509f-4e69-8c1e-ef311d583cd8"></a><a name="section-8.8"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Morphine sulfate pharmacokinetics are altered in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Clearance is decreased and the metabolites, M3G and M6G, may accumulate to much higher plasma levels in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> as compared to patients with normal renal function. Start these patients cautiously with lower doses of morphine sulfate and titrated slowly while carefully monitoring for side effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_9507ade2-54c9-4bce-943b-114c6e4e4340"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_547ea0c7-7c4a-4d76-8675-a2301369bd5f"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First"><span class="Bold">Morphine sulfate is a mu-agonist opioid and is a Schedule II controlled substance. Morphine sulfate, like other opioids used in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, can be abused and is subject to criminal diversion.</span></p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_c07701e8-4e30-4337-892f-4cea2b6118bf"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common.</p>
<p>“Drug-seeking? behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss? of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping? to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. The converse is also true. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p><span class="Bold">Morphine sulfate is intended for oral use only. Abuse of morphine sulfate poses a risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The risk is increased with concurrent abuse of alcohol and other substances. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and HIV.</span></p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
<p><span class="Bold">Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms. <span class="Italics">[See </span><span class="Italics"><a href="#i4i_specific_populations_id_3bceb606-db8f-4774-a89a-e58b8a200922">USE IN SPECIFIC POPULATIONS (8.2)</a> ]</span></span></p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="i4i_dependence_id_5e677bf8-24a2-4b6b-af6c-54f9a90a7c33"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is the need for increasing doses of opioids to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are not unusual during chronic opioid therapy.</p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate.</p>
<p>In general, taper opioids rather than abruptly discontinue.<span class="Italics"> [See </span><span class="Italics"><a href="#i4i_dosage_admin_id_94261fb9-045e-405c-b366-220c961aa97f">DOSAGE AND ADMINISTRATION (2.5)</a></span><span class="Italics">]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a84e7a72-7acb-42d5-9492-80b3f8e0d84c"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67370d30-4ea7-425f-b4ea-8956a23e1df4"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Symptoms</h2>
<p class="First">Acute overdosage with morphine sulfate is manifested by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">constricted pupils</span>, and, in some cases, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Morphine sulfate may cause <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, even in total darkness. Pinpoint pupils are a sign of opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> rather than <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> may be seen with <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations. <span class="Italics">[See </span><span class="Italics"><a href="#i4i_clinical_pharmacology_id_d52fa610-0406-4275-9361-c3180ea1b10a">CLINICAL PHARMACOLOGY (12)</a></span><span class="Italics">]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a4689961-aa6a-4d80-b807-e01f3de8e1fb"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Treatment</h2>
<p class="First">Give primary attention to re-establishment of a patent airway and institution of assisted or controlled ventilation. Employ supportive measures (including oxygen and vasopressors) in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation.</p>
<p>The pure opioid antagonists, naloxone or nalmefene, are specific antidotes to <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> resulting from opioid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Since the duration of reversal is expected to be less than the duration of action of morphine sulfate, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to opioid antagonists is sub-optimal or only brief in nature, administer additional antagonist as directed by the manufacturer of the product.</p>
<p>Do not administer opioid antagonists in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> secondary to morphine sulfate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Administer such agents cautiously to persons who are known, or suspected to be physically dependent on morphine sulfate. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome.</p>
<p>In an individual physically dependent on opioids, administration of the usual dose of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the dose of the antagonist administered. Reserve use of an opioid antagonist for cases where such treatment is clearly needed. If it is necessary to treat serious <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the physically dependent patient, initiate administration of the antagonist with care and titrate with smaller than usual doses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f9f94ffb-ac7f-4e5a-bbbb-493c425541a9"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Chemically, morphine sulfate is 7,8-didehydro-4,5 alpha-epoxy-17 methyl-morphinan-3,6 alpha-diol sulfate (2:1) (salt) pentahydrate with a molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of 758. Morphine sulfate occurs as white, feathery, silky crystals; cubical <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span> of crystal; or white crystalline powder. It is soluble in water and slightly soluble in alcohol, but is practically insoluble in chloroform or ether. The octanol:water partition coefficient of morphine is 1.42 at physiologic pH and the pK<span class="Sub">a</span> is 7.9 for the tertiary nitrogen (the majority is ionized at pH 7.4).</p>
<div class="Figure"><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67b3273e-af71-4dac-8e49-8bc134d4c591&amp;name=716a8e9c-ea77-4e74-8ace-9aa2c55a395a-01.jpg"></div>
<p>Each tablet contains 15 or 30 mg of morphine sulfate, USP and the following inactive ingredients: colloidal silicon dioxide, corn starch, microcrystalline cellulose, pregelatinized starch, and stearic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_d52fa610-0406-4275-9361-c3180ea1b10a"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_5e50acbb-1266-4063-86e6-56b834167312"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Morphine sulfate, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. In addition to <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, the widely diverse effects of morphine sulfate include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, changes in mood, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, decreased gastrointestinal motility, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and alterations of the endocrine and autonomic nervous system.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99104196-a781-43fd-8a88-0e797c1e4b51"></a><a name="section-12.1.1"></a><p></p>
<h3>Effects on the Central Nervous System (CNS) </h3>
<p class="First">The principal therapeutic action of morphine sulfate is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Other therapeutic effects of morphine sulfate include anxiolysis, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> and feelings of relaxation. Although the precise mechanism of the analgesic action is unknown, specific CNS opiate receptors and endogenous compounds with morphine sulfate-like activity have been identified throughout the brain and spinal cord and are likely to play a role in the expression and perception of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span>. In common with other opioids, morphine sulfate causes <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, in part by a direct effect on the brainstem respiratory centers. Morphine sulfate and related opioids depress the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center in the medulla. </p>
<p>Morphine sulfate causes <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, even in total darkness. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e70c8684-d993-4540-be9c-dc8662ce4933"></a><a name="section-12.1.2"></a><p></p>
<h3>Effects on the Gastrointestinal Tract and on Other Smooth Muscle </h3>
<p class="First">Gastric, biliary and pancreatic secretions are decreased by morphine sulfate. Morphine sulfate causes a reduction in motility and is associated with an increase in tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone is increased to the point of spasm. The end result may be <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Morphine sulfate can cause a marked increase in biliary tract pressure as a result of spasm of the sphincter of Oddi. Morphine sulfate may also cause spasm of the sphincter of the urinary bladder.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cd15af14-1b68-42a8-ad6f-49a1afca08b4"></a><a name="section-12.1.3"></a><p></p>
<h3>Effects on the Cardiovascular System</h3>
<p class="First">In therapeutic doses, morphine sulfate does not usually exert major effects on the cardiovascular system. Morphine sulfate produces peripheral vasodilation which may result in <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. Release of histamine can occur, which may play a role in opioid-induced <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Manifestations of histamine release and/or peripheral vasodilation may include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4be7fa79-fcbd-473b-97b4-d7b593fce11f"></a><a name="section-12.1.4"></a><p></p>
<h3>Endocrine System</h3>
<p class="First">Opioid agonists have been shown to have a variety of effects on the secretion of hormones. Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species, rats and dogs. Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff1b79ff-c3ea-4651-be84-9308046f7233"></a><a name="section-12.1.5"></a><p></p>
<h3>Immune System</h3>
<p class="First">Opioids have been shown to have a variety of effects on components of the immune system in <span class="Italics">in vitro </span>and animal models. The clinical significance of these findings is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_a897b41e-01d2-4c70-81ab-58594e55c6f3"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Morphine sulfate concentrations are not predictive of analgesic response, especially in patients previously treated with opioids. The minimum effective concentration varies widely and is influenced by a variety of factors, including the extent of previous opioid use, age and general medical condition. Effective doses in tolerant patients may be significantly higher than in opioid-naïve patients.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a3fb2b90-cd7c-4d65-acbe-6e5ee0ead6a8"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39a7990e-f089-40b1-a4fb-352c5f59bfa2"></a><a name="section-12.3.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Morphine sulfate is about two-thirds absorbed from the gastrointestinal tract with the maximum <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> occurring 60 minutes post-administration. The oral bioavailability of morphine sulfate is less than 40% and shows large inter-individual variability due to extensive pre-systemic metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f84210b-2b92-4003-96ad-e538348e0532"></a><a name="section-12.3.2"></a><p></p>
<h3>Food Effects   </h3>
<p class="First">When morphine sulfate 30 mg tablet was administered 30 minutes after ingesting a high fat/high calorie meal, there was no change in the extent of absorption (AUC) of morphine sulfate. There was, however, an increase in the median T<span class="Sub">max</span> from 0.5 to 0.75 hours and an 11% decrease in C<span class="Sub">max</span>. The tablet can be administered without regard to meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15f7d1f5-53cd-4fec-bb94-10048712b99c"></a><a name="section-12.3.3"></a><p></p>
<h3>Steady-State</h3>
<p class="First">Administration of the 30 mg Morphine Sulfate Tablet and 30 mg of Morphine Sulfate Oral Solution every six hours for 5 days resulted in a comparable 24-hour exposure (AUC). The steady-state levels were achieved within 48 hours for both tablets and solution. The mean steady state C<span class="Sub">max</span> values were about 78 and 58 ng/mL for tablet and solution, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d5741c2-bec4-4bb4-a746-3c99dcc388df"></a><a name="section-12.3.4"></a><p></p>
<h3>Distribution </h3>
<p class="First">Once absorbed, morphine sulfate is distributed to skeletal muscle, kidneys, liver, intestinal tract, lungs, spleen and brain. Although the primary site of action is the CNS, only small quantities cross the blood-brain barrier. Morphine sulfate also crosses the placental membranes and has been found in breast milk. The volume of distribution of morphine sulfate is approximately 1 to 6 L/kg, and morphine sulfate is 20 to 35% reversibly bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea849ae6-9203-4e06-8797-6f53ef8e82a8"></a><a name="section-12.3.5"></a><p></p>
<h3>Metabolism </h3>
<p class="First">The major pathway of morphine sulfate detoxification is conjunction, either with D-glucuronic acid to produce glucuronides or with sulfuric acid to produce morphine-3-etheral sulfate. While a small fraction (less than 5%) of morphine sulfate is demethylated, virtually all morphine sulfate is converted by hepatic metabolism to the 3- and 6-glucuronide metabolites (M3G and M6G; about 50% and 15%, respectively). M6G has been shown to have analgesic activity but crosses the blood-brain barrier poorly, while M3G has no significant analgesic activity. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b94fff7d-1c36-46bc-82c7-00d3495dda2c"></a><a name="section-12.3.6"></a><p></p>
<h3>Excretion </h3>
<p class="First">Most of a dose of morphine sulfate is excreted in urine as M3G and M6G, with elimination of morphine sulfate occurring primarily as renal excretion of M3G. Approximately 10% of the dose is excreted unchanged in urine. A small amount of glucuronide conjugates are excreted in bile, with minor enterohepatic recycling. Seven to 10% of administered morphine sulfate is excreted in the feces.</p>
<p>The mean adult plasma clearance is approximately 20 to 30 mL/min/kg. The effective terminal half-life of morphine sulfate after IV administration is reported to be approximately 2 hours. In some studies involving longer periods of plasma sampling, a longer terminal half-life of morphine sulfate of about 15 hours was reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a55b1d71-c07d-42a4-bbae-04c2093eec50"></a><a name="section-12.3.7"></a><p></p>
<h3>Race</h3>
<p class="First">There may be some pharmacokinetic differences associated with race. In one published study, Chinese subjects given intravenous morphine sulfate had a higher clearance when compared to Caucasian subjects (1852 +/- 116 mL/min compared to 1495 +/- 80 mL/min).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_a96f0c48-aa69-4ead-af51-e34aa6898e1f"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_09ea55a1-a7b6-4595-9bd9-f1b36ec0e1a6"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies in animals to evaluate the carcinogenic potential of morphine sulfate have not been conducted. No formal studies to assess the mutagenic potential of morphine sulfate have been conducted. In the published literature, the results of <span class="Italics">in vitro</span> studies showed that morphine sulfate is non-mutagenic in the <span class="Italics">Drosophila melanogaster</span> lethal mutation assay and produced no evidence of chromosomal aberrations when incubated with murine splenocytes. Contrary to these results, morphine sulfate was found to increase DNA fragmentation when incubated <span class="Italics">in vitro</span> with a human <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> line. <span class="Italics">In vivo</span>, morphine sulfate has been reported to produce an increase in the frequency of micronuclei in bone marrow cells and immature red blood cells in the mouse micronucleus test and to induce chromosomal aberrations in murine <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and spermatids. Some of the <span class="Italics">in vivo </span>clastogenic effects reported with morphine sulfate in mice may be directly related to increases in glucocorticoid levels produced by morphine sulfate in this species. </p>
<p>A literature report indicated that morphine sulfate impairs fertility in rats. In a fertility study in which male rats were administered morphine sulfate subcutaneous prior to mating (up to 30 mg/kg twice daily) and during mating (20 mg/kg twice daily) with untreated females, a number of adverse reproductive effects were observed. These included reduction in total pregnancies, higher incidence of pseudopregnancies, and reduction in implantation sites.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a8569101-81f2-4b77-ac10-28885a1dbad1"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">Morphine Sulfate Tablets</span></p>
<p><span class="Bold">15 mg Tablet:</span> white, biconvex tablets scored on one side and product identification "54 733" debossed on the other side.</p>
<p>Unit dose, 25 tablets per card</p>
<p>NDC 0054-0235-24: 4 Cards Per Carton</p>
<p>NDC 0054-0235-25: Bottle of 100 Tablets</p>
<p><span class="Bold">30 mg Tablet:</span> white, biconvex tablets scored on one side and product identification "54 262" debossed on the other side.</p>
<p>Unit dose, 25 tablets per card</p>
<p>NDC 0054-0236-24: 4 Cards Per Carton</p>
<p>NDC 0054-0236-25: Bottle of 100 Tablets<br></p>
<p><span class="Bold">Storage</span></p>
<p>Store at Controlled Room Temperature, 15° to 30°C (59° to 86°F).</p>
<p>PROTECT FROM MOISTURE.</p>
<p>All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ee28015f-3754-4ebe-bb4b-928fcdfb82b0"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Provide the following information to patients receiving morphine sulfate or their caregivers:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b75639e-2a42-41fe-9945-6cba4b7a0680"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Information for Patients and Caregivers</h2>
<ul>
<li>Advise patients that morphine sulfate is a narcotic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> reliever, and should be taken only as directed.</li>
<li>Advise patients not to adjust the dose of morphine sulfate without consulting with a physician or other healthcare professional.</li>
<li>Advise patients that morphine sulfate may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). Advise patients started on morphine sulfate or patients whose dose has been adjusted to refrain from any potentially dangerous activity until it is established that they are not adversely affected.</li>
<li>Advise patients that morphine sulfate will add to the effect of alcohol and other CNS depressants (such as antihistamines, sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, and monoamine oxidase [MAO] inhibitors).</li>
<li>Instruct patients not to combine morphine sulfate with central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, and not to combine with alcohol because dangerous additive effects may occur, resulting in serious injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>Instruct women of childbearing potential who become or are planning to become pregnant to consult a physician prior to initiating or continuing therapy with morphine sulfate. </li>
<li>Advise patients that safe use in pregnancy has not been established and that prolonged use of opioid analgesics during pregnancy may cause fetal-neonatal physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and neonatal withdrawal may occur.</li>
<li>If patients have been receiving treatment with morphine sulfate for more than a few weeks and cessation of therapy is indicated, counsel them on the importance of safely tapering the dose and that abruptly discontinuing the medication could precipitate withdrawal symptoms. Provide a dose schedule to accomplish a gradual discontinuation of the medication.</li>
<li>Advise patients that morphine sulfate is a potential drug of abuse. They must protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>. It should never be given to anyone other than the individual for whom it was prescribed.</li>
<li>Instruct patients to keep morphine sulfate in a secure place out of the reach of children. When morphine sulfate is no longer needed, the unused tablets should be destroyed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> down the toilet.</li>
<li>Advise patients taking morphine sulfate of the potential for severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; appropriate laxatives and/or stool softeners as well as other appropriate treatments should be initiated from the onset of opioid therapy.</li>
<li>Advise patients of the most common adverse events that may occur while taking morphine sulfate: <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</li>
</ul>
<p class="First">10004596/02</p>
<p>Revised January 2010</p>
<p>©RLI, 2010</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_54b9fe39-5e44-4a5e-9c48-1f70a55b6356"></a><a name="section-16"></a><p></p>
<h1>Medication Guide</h1>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_399c84ba-8467-4cf0-a3fd-6552c5904c94"></a><a name="section-17"></a><p></p>
<h1>NDC 0054-0236-25: Bottle of 100 Tablets<br>
</h1>
<div class="Figure"><img alt="NDC 66336-0502-XX" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67b3273e-af71-4dac-8e49-8bc134d4c591&amp;name=NDC%2066336-0502-XX------ROXANE.jpg"></div>
<p class="First">NDC 66336-0502-XX</p>
<p>NDC 66336-0502-30</p>
<p>NDC 66336-0502-60</p>
<p>NDC 66336-0502-90</p>
<p class="First MultiMediaCaption"></p>
<p class="MultiMediaCaption"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MORPHINE SULFATE 		
					</strong><br><span class="contentTableReg">morphine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66336-502(NDC:0054-0236)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MORPHINE SULFATE</strong> (MORPHINE) </td>
<td class="formItem">MORPHINE SULFATE</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;262</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66336-502-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66336-502-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:66336-502-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022207</td>
<td class="formItem">03/17/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dispensing Solutions, Inc.
							(066070785)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PSS World Medical, Inc. (101822682)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dispensing Solutions, Inc.</td>
<td class="formItem"></td>
<td class="formItem">066070785</td>
<td class="formItem">relabel(66336-502), repack(66336-502)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f7aa7607-6319-4a5e-9a21-3a3e97b2e499</div>
<div>Set id: 67b3273e-af71-4dac-8e49-8bc134d4c591</div>
<div>Version: 1</div>
<div>Effective Time: 20130408</div>
</div>
</div> <div class="DistributorName">Dispensing Solutions, Inc.</div></p>
</body></html>
